Maurizio Callari

10PUBLICATIONS
109CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer geneticsPharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jan 26, 2026
Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.

Giampaolo Bianchini, Luca Malorni, Roberta Caputo

|Mar 04, 2025
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies.

Maurizio Callari, Matteo Dugo, Marco Barreca

|Nov 08, 2024
Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer.

Abigail Shea, Yaniv Eyal-Lubling, Daniel Guerrero-Romero

|Oct 25, 2024
Development and validation of a gene expression-based Breast Cancer Purity Score.

Marco Barreca, Matteo Dugo, Barbara Galbardi

|Sep 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.

Matteo Dugo, Chiun-Sheng Huang, Daniel Egle

|Feb 21, 2024
Converging and evolving immuno-genomic routes toward immune escape in breast cancer.

Juan Blanco-Heredia, Carla Anjos Souza, Juan L Trincado

Pageof 2

Frequent Collaborators

5 joint publications

Giampaolo Bianchini

3 joint publications

Pinuccia Valagussa

3 joint publications

Lucia Del Mastro

3 joint publications

Lajos Pusztai